Recently, China National Intellectual Property Administration announced the winners of the 21st China Patent Award. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. ("Hansoh Pharma") won the China Patent Excellence Award for its invention patent "Application of α-(morpholin-1-yl)methyl-2-methyl-5-nitroimidazole-1-ethanol in preparation of anti-anaerobic drugs" (patented product: Mailingda). "China Patent Award" is the highest award in the field of intellectual property in China, and the winners are jointly selected by China National Intellectual Property Administration and the World Intellectual Property Organization. This patent award received by Hansoh Pharma is another national affirmation of its intellectual property strength and technological innovation capability following its cumulative receipt of 1 gold medal and 5 excellence awards before. At the same time, Hansoh Pharma's invention patent, "Tigecycline pharmaceutical composition and its preparation method" (patented product: Zetan) won the China Patent Silver Award.
China Patent Excellence Award
Mailingda provides new drug choice for doctors and patients
The invention patent "Application of α-(morpholin-1-yl)methyl-2-methyl-5-nitroimidazole-1-ethanol in preparation of anti-anaerobic drugs", which won the China Patent Excellence Award this time, innovatively applies the corresponding compound "morpholinidazole" to clinical treatment. The patented product Mailingda (Morinidazole and Sodium Chloride Injection), a national Class 1 innovative drug, was launched in 2014. It is the first nitroimidazole anti-anaerobic innovative drug in the world over 40 years and the first nitroimidazole anti-infective drug with independent intellectual property rights in China, for the treatment of anaerobic infectious diseases such as pelvic inflammatory disease and appendicitis. As a new third-generation nitroimidazole drug, clinical data of Mailingda show that, compared with previous generations of nitroimidazole drugs, it has strong antibacterial activity, rapid onset of action, good tolerance and high safety, does not require dosage adjustment for patients with mild to moderate liver insufficiency, has good curative effect on surgical infection and gynecological infection caused by anaerobic bacteria, and has been included as one of the key recommended drugs for the treatment of abdominal infection in China's Guidelines for Diagnosis and Treatment of Abdominal Infection (2019 Edition). The launch of Mailingda has promoted the development of the anti-anaerobic field, especially in terms of drug safety, effectively reducing the medication risks of patients. It also has good clinical value, and is now on the national reimbursement drug list.
Standardizing intellectual property management; enabling innovative development
The pharmaceutical industry is an innovation-intensive industry, with a relatively high concentration of intellectual property. Since its inception, Hansoh Pharma has attached great importance to the development and accumulation of intellectual property. Relying on its solid R&D strength and perfect management system, Hansoh Pharma has persistently tackled scientific research and technical barriers, developed a large number of key core technologies, and obtained a batch of core high-value drug patents. With excellent intellectual property management and independent innovation capability, Hansoh Pharma has been rated as a national intellectual property demonstration enterprise. At the same time, through continuous improvement and development, Hansoh Pharma has been certified as a national standard conformity entity under the Enterprise Intellectual Property Management System, has been selected as a pilot entity for national patent collaborative application and a pilot entity for national industrial enterprise intellectual property application capability cultivation project, and has achieved fruitful intellectual property results. Up to June 2020, Hansoh Pharma has undertaken more than 40 national-level scientific research projects including 863 Program, "Major New Drug Innovation and Development" Science and Technology Special Project, and Torch Program; has won 2 second prizes in the National Scientific and Technological Progress Award and 1 gold medal in China Patent Award; and has been granted more than 300 invention patents at home and abroad on a cumulative basis.
Hansoh Pharma has always adhered to the strategy of scientific and technological innovation. The award is not only a great affirmation and encouragement to its intellectual property work over the years, but also will promote the further implementation of its intellectual property strategy and the improvement of its intellectual property management, independent innovation capability and core competitiveness. Living up to the corporate mission to "create excellence in pharmaceuticals, enhance innovation in China", Hansoh Pharma will make further efforts to continuously improve its intellectual property management and independent innovation capability, and continue to contribute its strength to help promote the innovation-driven development strategy, promote the national intellectual property strategy, and build China into a powerful country in intellectual property.
